TC BioPharm reports complete response in MRD patient after 2nd dose of TCB008. First in Cohort B.Announced in Edinburgh.
A patient in Cohort B has successfully achieved complete remission after receiving their second dose of TCB008 in Edinburgh, Scotland. This significant development was reported by TC BioPharm (Holdings) PLC, a company listed on NASDAQ under the ticker symbol TCBP. They specialize in developing cutting-edge gamma delta T cell therapies to combat cancer. This breakthrough marks a critical milestone in the field of cancer treatment and highlights the promising potential of this innovative therapy.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments